Clinical Trial: A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234591) titled 'A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis' on Nov. 14.

Brief Summary: A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

Study Start Date: Oct. 21

Study Type: INTERVENTIONAL

Condition: Plaque Psoriasis Moderate to Severe Plaque Psoriasis

Intervention: DRUG: Tyk2 inhibitor

Specific dose of Tyk2 inhibitor on specific days

DRUG: Placebo

Specified dose of Placebo on specified days.

Recruitment Status: RECRUITING

Sponsor: Usynova Pharmaceuticals Ltd.

Published by HT D...